The efficacy of Denosumab in the treatment of femoral head osteonecrosis: a retrospective comparative study
Abstract The present study aimed to compare clinical and radiological differences of ONFH patients who were treated with denosumab, and a control group. A total of 178 patients (272 hips) with symptomatic, nontraumatic ONFH were divided into a denosumab group (98 patients, 146 hips) and a control gr...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-02-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-54685-7 |
| _version_ | 1797275229519609856 |
|---|---|
| author | Jun-Ki Moon Jinyong Park Yisack Yoo Jae Youn Yoon Sunhyung Lee Pil Whan Yoon |
| author_facet | Jun-Ki Moon Jinyong Park Yisack Yoo Jae Youn Yoon Sunhyung Lee Pil Whan Yoon |
| author_sort | Jun-Ki Moon |
| collection | DOAJ |
| description | Abstract The present study aimed to compare clinical and radiological differences of ONFH patients who were treated with denosumab, and a control group. A total of 178 patients (272 hips) with symptomatic, nontraumatic ONFH were divided into a denosumab group (98 patients, 146 hips) and a control group (80 patients, 126 hips). Patients in the denosumab group received a 60 mg subcutaneous dose of denosumab every 6 months. For the clinical assessments, Harris hip scores (HHS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) were evaluated. Plain radiographs and MRI were performed before and a minimum of 1 year after administration of denosumab, which were evaluated for radiological results including femoral head collapse (≥ 2 mm) and volume change of necrotic lesion. Femoral head collapse occurred in 36 hips (24.7%) in the denosumab group, and 48 hips (38.1%) in the control group, which was statistically significant (P = 0.012). Twenty-three hips (15.8%) in the denosumab group and 29 hips (23%) in the control group required THA, which showed no significant difference (P = 0.086). At the final follow-up, 71.9% of hips in the denosumab group had a good or excellent HHS compared with 48.9% in the control group, showing a significant difference (P = 0.012). The denosumab group showed a significantly higher rate of necrotic lesion volume reductions compared with the control group (P < 0.001). Denosumab can significantly reduce the volume of necrotic lesions and prevent femoral head collapse in patients with ARCO stage I or II ONFH. |
| first_indexed | 2024-03-07T15:10:24Z |
| format | Article |
| id | doaj.art-b48ebc5cc9084b20b1d7aa891cdf53e2 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-07T15:10:24Z |
| publishDate | 2024-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-b48ebc5cc9084b20b1d7aa891cdf53e22024-03-05T18:41:56ZengNature PortfolioScientific Reports2045-23222024-02-011411810.1038/s41598-024-54685-7The efficacy of Denosumab in the treatment of femoral head osteonecrosis: a retrospective comparative studyJun-Ki Moon0Jinyong Park1Yisack Yoo2Jae Youn Yoon3Sunhyung Lee4Pil Whan Yoon5Department of Orthopaedic Surgery, Chung-Ang University Hospital, Chung-Ang University College of MedicineDepartment of Orthopedic Surgery, Asan Medical CenterDepartment of Orthopaedic Surgery, Chung-Ang University Hospital, Chung-Ang University College of MedicineDepartment of Orthopedic Surgery, Seoul Now HospitalDepartment of Orthopedic Surgery, Seoul National University Boramae Medical CenterDepartment of Orthopedic Surgery, Seoul Now HospitalAbstract The present study aimed to compare clinical and radiological differences of ONFH patients who were treated with denosumab, and a control group. A total of 178 patients (272 hips) with symptomatic, nontraumatic ONFH were divided into a denosumab group (98 patients, 146 hips) and a control group (80 patients, 126 hips). Patients in the denosumab group received a 60 mg subcutaneous dose of denosumab every 6 months. For the clinical assessments, Harris hip scores (HHS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) were evaluated. Plain radiographs and MRI were performed before and a minimum of 1 year after administration of denosumab, which were evaluated for radiological results including femoral head collapse (≥ 2 mm) and volume change of necrotic lesion. Femoral head collapse occurred in 36 hips (24.7%) in the denosumab group, and 48 hips (38.1%) in the control group, which was statistically significant (P = 0.012). Twenty-three hips (15.8%) in the denosumab group and 29 hips (23%) in the control group required THA, which showed no significant difference (P = 0.086). At the final follow-up, 71.9% of hips in the denosumab group had a good or excellent HHS compared with 48.9% in the control group, showing a significant difference (P = 0.012). The denosumab group showed a significantly higher rate of necrotic lesion volume reductions compared with the control group (P < 0.001). Denosumab can significantly reduce the volume of necrotic lesions and prevent femoral head collapse in patients with ARCO stage I or II ONFH.https://doi.org/10.1038/s41598-024-54685-7 |
| spellingShingle | Jun-Ki Moon Jinyong Park Yisack Yoo Jae Youn Yoon Sunhyung Lee Pil Whan Yoon The efficacy of Denosumab in the treatment of femoral head osteonecrosis: a retrospective comparative study Scientific Reports |
| title | The efficacy of Denosumab in the treatment of femoral head osteonecrosis: a retrospective comparative study |
| title_full | The efficacy of Denosumab in the treatment of femoral head osteonecrosis: a retrospective comparative study |
| title_fullStr | The efficacy of Denosumab in the treatment of femoral head osteonecrosis: a retrospective comparative study |
| title_full_unstemmed | The efficacy of Denosumab in the treatment of femoral head osteonecrosis: a retrospective comparative study |
| title_short | The efficacy of Denosumab in the treatment of femoral head osteonecrosis: a retrospective comparative study |
| title_sort | efficacy of denosumab in the treatment of femoral head osteonecrosis a retrospective comparative study |
| url | https://doi.org/10.1038/s41598-024-54685-7 |
| work_keys_str_mv | AT junkimoon theefficacyofdenosumabinthetreatmentoffemoralheadosteonecrosisaretrospectivecomparativestudy AT jinyongpark theefficacyofdenosumabinthetreatmentoffemoralheadosteonecrosisaretrospectivecomparativestudy AT yisackyoo theefficacyofdenosumabinthetreatmentoffemoralheadosteonecrosisaretrospectivecomparativestudy AT jaeyounyoon theefficacyofdenosumabinthetreatmentoffemoralheadosteonecrosisaretrospectivecomparativestudy AT sunhyunglee theefficacyofdenosumabinthetreatmentoffemoralheadosteonecrosisaretrospectivecomparativestudy AT pilwhanyoon theefficacyofdenosumabinthetreatmentoffemoralheadosteonecrosisaretrospectivecomparativestudy AT junkimoon efficacyofdenosumabinthetreatmentoffemoralheadosteonecrosisaretrospectivecomparativestudy AT jinyongpark efficacyofdenosumabinthetreatmentoffemoralheadosteonecrosisaretrospectivecomparativestudy AT yisackyoo efficacyofdenosumabinthetreatmentoffemoralheadosteonecrosisaretrospectivecomparativestudy AT jaeyounyoon efficacyofdenosumabinthetreatmentoffemoralheadosteonecrosisaretrospectivecomparativestudy AT sunhyunglee efficacyofdenosumabinthetreatmentoffemoralheadosteonecrosisaretrospectivecomparativestudy AT pilwhanyoon efficacyofdenosumabinthetreatmentoffemoralheadosteonecrosisaretrospectivecomparativestudy |